Victory Capital Management Inc. Buys 224,190 Shares of SiBone (NASDAQ:SIBN)

Victory Capital Management Inc. raised its stake in SiBone (NASDAQ:SIBN - Free Report) by 55.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 631,568 shares of the company's stock after acquiring an additional 224,190 shares during the quarter. Victory Capital Management Inc. owned approximately 1.49% of SiBone worth $8,861,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in SIBN. Johnson Investment Counsel Inc. acquired a new stake in SiBone in the 1st quarter valued at $148,000. Rhumbline Advisers raised its stake in SiBone by 3.6% in the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company's stock valued at $838,000 after acquiring an additional 2,100 shares during the period. MetLife Investment Management LLC increased its position in shares of SiBone by 17.6% during the fourth quarter. MetLife Investment Management LLC now owns 27,421 shares of the company's stock valued at $384,000 after buying an additional 4,104 shares during the period. Deutsche Bank AG grew its holdings in shares of SiBone by 53.0% during the fourth quarter. Deutsche Bank AG now owns 36,268 shares of the company's stock worth $508,000 after purchasing an additional 12,561 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of SiBone by 8.3% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 102,666 shares of the company's stock worth $1,439,000 after purchasing an additional 7,855 shares in the last quarter. Institutional investors and hedge funds own 98.11% of the company's stock.

Wall Street Analysts Forecast Growth

SIBN has been the subject of a number of recent analyst reports. Truist Financial upped their target price on SiBone from $20.00 to $22.00 and gave the company a "buy" rating in a report on Tuesday, May 6th. Cantor Fitzgerald reissued an "overweight" rating and issued a $25.00 target price on shares of SiBone in a research note on Tuesday, May 6th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $24.00 price objective on shares of SiBone in a research report on Tuesday, May 6th.

SiBone Trading Down 0.6%

Shares of SiBone stock traded down $0.11 on Friday, reaching $17.25. The company had a trading volume of 208,797 shares, compared to its average volume of 344,467. The firm has a market cap of $735.20 million, a price-to-earnings ratio of -26.95 and a beta of 0.93. The company has a debt-to-equity ratio of 0.21, a current ratio of 8.53 and a quick ratio of 7.26. The firm's 50-day moving average price is $18.05 and its two-hundred day moving average price is $16.54. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05.

SiBone (NASDAQ:SIBN - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.15) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.09. SiBone had a negative return on equity of 16.00% and a negative net margin of 15.03%. The firm had revenue of $47.29 million during the quarter, compared to analysts' expectations of $45.13 million. As a group, research analysts predict that SiBone will post -0.78 earnings per share for the current fiscal year.

Insider Activity at SiBone

In related news, insider Anthony J. Recupero sold 4,147 shares of the business's stock in a transaction on Friday, May 16th. The stock was sold at an average price of $19.56, for a total transaction of $81,115.32. Following the completion of the transaction, the insider owned 282,015 shares in the company, valued at $5,516,213.40. The trade was a 1.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Laura Francis sold 38,504 shares of the company's stock in a transaction on Wednesday, May 7th. The stock was sold at an average price of $17.18, for a total value of $661,498.72. Following the completion of the sale, the chief executive officer owned 302,958 shares of the company's stock, valued at $5,204,818.44. This represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 101,702 shares of company stock worth $1,866,404 over the last quarter. 4.00% of the stock is owned by insiders.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.